Julian A. Torres Isasiga

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/4629f8b0-5f9e-11ec-adc9-0ba7483a687b.jpg

First Name

Julian

Last Name

Torres Isasiga

NPI

1912277419

Faculty ID

15594

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Torres completed his MD degree at Universidad del Valle (Cali, Colombia) in 2006. He then joined the International Center for Training and Medical Research (CIDEIM) in his home town, Cali, where he spent almost 3 years as a research assistant in the area of Gram negative Bacterial Resistance, where he published and presented his work in national and international journals and conferences.</p>
<p>After completing his Internal Medicine residency at Jacobi Medical Center in the Bronx, Dr. Torres completed his fellowship in Infectious Diseases at New York University (NYU). He then joined Englewood Hospital where he spent more than 2 years as an Infectious Disease consultant.</p>
<p>Dr. Torres joined Montefiore Medical Center/Albert&nbsp;Einstein&nbsp;College of Medicine&nbsp;in 2017 as an Assistant Professor. Since then, he has been providing PrEP, PEP, STI, HCV&nbsp;and HIV care to patients in the Bronx, as well as inpatient Infectious Disease consultation services at the hospital.&nbsp; He has an interest to expand HIV prevention projects in Colombia and is working closely with Corporacion de Lucha contra el SIDA in Cali.</p>
<p>Dr. Torres has been a member of the Infectious Disease Society of America since 2012.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p align="left"><strong><span style="font-family: Times New Roman; font-size: medium;">Selected Publications</span></strong><strong><span style="text-decoration: underline;"><span style="font-family: Times New Roman; font-size: medium;"><br /></span></span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span lang="ES" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">&middot;<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">Nori P, Szymczak W, Puius J, Sharma A, Cowman K, Fleischner Z, Bartash R, Chen V, Corpuz M, Gialanella P, Alpert P, Felsen U,<strong> Torres-Isasiga J</strong>, Guo Y. </span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">Emerging Co-Pathogens: New Delhi Metallo-beta-lactamase producing Enterobacterales Infections in New York City COVID-19 Patients. &nbsp;</span><span lang="ES" style="color: black; mso-color-alt: windowtext;">Int J Antimicrob Agents. 56(6):106179. doi: 10.1016/j.ijantimicag.2020.106179.&nbsp;Epub 2020 Sep 25.<strong> (2020)</strong></span></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">&middot;<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">Mueses-Mar&iacute;n HF, Alvarado-Llano B, </span><strong style="mso-bidi-font-weight: normal;"><span lang="ES" style="color: black; mso-color-alt: windowtext;">Torres-Isasiga J</span></strong><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">, Camargo-Plazas P, Bol&iacute;var-Rocha MC, Galindo-Orrego X, Mart&iacute;nez-Cajas JL. </span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">Scales to Assess Knowledge, Motivation, and Self-Efficacy for HIV PrEP in Colombian MSM: PrEP-COL Study. AIDS Research and Treatment, vol. 2021, Article ID 4789971, 11 pages </span><strong style="mso-bidi-font-weight: normal;"><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">(2021)</span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span lang="ES" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">&middot;<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">Falsey AR, et al., </span><strong style="mso-bidi-font-weight: normal;"><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">and the AstraZeneca AZD1222 Clinical Study Group (Julian A. Torres). </span></strong><span lang="ES" style="color: black; mso-color-alt: windowtext;"><a href="https://pubmed.ncbi.nlm.nih.gov/34587382/"><span lang="EN-US" style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold; text-decoration: none; text-underline: none;">Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine</span></a></span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">. </span><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">N Engl J Med. </span><span lang="ES" style="font-size: 10.5pt; font-family: 'Segoe UI',sans-serif; color: #4d8055; background: white;">&nbsp;</span><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">doi: 10.1056/NEJMoa21052902021. </span><strong style="mso-bidi-font-weight: normal;"><span lang="ES" style="color: black; mso-color-alt: windowtext;">(2021).</span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">&middot;<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">Mart&iacute;nez-Cajas J, Alvarado-Llano B, Mart&iacute;nez-Buitrago E,&nbsp;<strong>Torres-Isasiga J</strong>, Arrivillaga M, Camargo P, Galindo-Orrego X, Mueses-Mar&iacute;n H. </span><span lang="ES" style="color: black; mso-color-alt: windowtext;"><a href="https://pubmed.ncbi.nlm.nih.gov/35067114/"><span lang="EN-US" style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold; text-decoration: none; text-underline: none;">AC-2020-12-1420.R1 - HIV care providers' familiarity, concerns, and attitudes about HIV PrEP in Colombia: insights from the PrEP-Col-Study.</span></a></span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;"> AIDS Care. doi: 10.1080/09540121.2022.2029813 </span><strong style="mso-bidi-font-weight: normal;"><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">(2022)</span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">&middot;<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">Mart&iacute;nez-Cajas JL, <strong>Torres J, </strong>Mueses HF, Camargo Plazas P, Arrivillaga M, Gomez SA, Galindo X, Mart&iacute;nez Buitrago E,&nbsp;Alvarado-Llano BE. </span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">Applying Implementation Science Frameworks to&nbsp;Identify Factors that&nbsp;Influence the&nbsp;Intention of&nbsp;Healthcare Providers to&nbsp;Offer PrEP Care and&nbsp;Advocate for&nbsp;PrEP in&nbsp;HIV Clinics in&nbsp;Colombia: A&nbsp;Cross-Sectional Study. Implement Sci Commun. Mar 16; 3(1):31. doi.org/10.1186/s43058-022-00278-2 </span><strong style="mso-bidi-font-weight: normal;"><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">(2022)</span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span lang="ES" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">&middot;<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">Meyerowitz EA, Bernardo, RM, Collins-Ogle, MD, Mamber Czeresnia, J, Morales Matos, C, Mullis C, Root, H; <strong>Torres-Isasiga JA</strong>, Tsai, H; Zingman, B. Navigating HIV Screening Recommendations for People on PrEP and the Need to Update Testing Algorithms. </span><em><span lang="ES" style="color: black; mso-color-alt: windowtext;">Open Forum Infectious Diseases</span></em><span lang="ES" style="color: black; mso-color-alt: windowtext;">, ofac191. <a href="https://doi.org/10.1093/ofid/ofac191"><span style="color: black; mso-color-alt: windowtext; text-decoration: none; text-underline: none;">doi.org/10.1093/ofid/ofac191</span></a> <strong>(2022)</strong></span></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span lang="ES" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">&middot;<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang="ES-CO" style="color: black; mso-color-alt: windowtext; mso-ansi-language: ES-CO;">Arrivillaga M, G&oacute;mez SA, Mueses HF, Alvarado B, Mart&iacute;nez Buitrago E, Camargo-Plazas P, Hurtado LR, Bol&iacute;var MC, Galindo X, <strong>Torres J</strong>, Cajas-Mart&iacute;nez JL. Facilitadores y recomendaciones de proveedores de salud para la implementaci&oacute;n de la Profilaxis Pre-Exposici&oacute;n en cl&iacute;nicas de VIH en Colombia. &ldquo;Estudio PPrE-Colombia&rdquo;. Rev Gerenc Polit Salud;21. </span><span lang="ES" style="color: black; mso-color-alt: windowtext;"><a href="https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.o…; target="_blank" rel="noopener"><span lang="ES-CO" style="color: black; mso-color-alt: windowtext; mso-ansi-language: ES-CO; text-decoration: none; text-underline: none;">https://doi.org/10.11144/Javeriana.rgps21.frps</span></a></span><span lang="ES-CO" style="color: black; mso-color-alt: windowtext; mso-ansi-language: ES-CO;"> <strong>(2022)</strong></span></p>
<p class="MsoListParagraph" style="margin-left: 0.5in; text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><!-- [if !supportLists]--><span lang="ES-CO" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: ES-CO;">&middot;<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang="ES-CO">Meyerowitz EA, Gendlina I, Desai VJ, Grossberg R, Nair SR, Pujar B, Riska PF, Root HB, Toro J, <strong>Torres JA</strong>, Pirofski LA, Zingman BS. Anorectal Testing for Monkeypox Virus Infection in Men who have Sex with Men with and without Proctitis. Clin Infect Dis. 2022 Oct 13:ciac825. doi: 10.1093/cid/ciac825. Epub ahead of print. PMID: 36227656 <strong>(2022)</strong></span></p>

EMR ID

55957

Biography

<p>Julian A. Torres lsasiga, MD, is an attending physician at Montefiore Einstein and Associate Professor, Infectious Diseases at our Albert Einstein College of Medicine. Dr. Torres&rsquo;s clinical focus centers on general infectious disease care, HIV prevention and care, sexually transmitted infections and medical education.</p><p>After earning his Doctor of Medicine at the Universidad del Valle/Hospital Universitario del Valle in Cali, Colombia in 2006, Dr. Torres became a research assistant at the International Center for Medical Research and Training (CIDEIM) in Cali, Colombia, from 2007 to 2009. He then moved to the United States to continue his medical training, completing his internal medicine residency at Jacobi Medical Center in 2012 and an infectious disease fellowship at New York University in 2014.</p><p>Building on his clinical focus, Dr. Torres&rsquo;s research is focused on HIV prevention and pre-exposure prophylaxis (PrEP). He has been co-investigator, principal investigator and sub-investigator on several research projects and he has shared his work through many national and international invited presentations and poster presentations. Dr. Torres is a reviewer for <em>Clinical Infectious Disease, Open Forum Infectious Disease</em> and the <em>International Journal of STD &amp; AIDS</em>. His work has been published in numerous peer-reviewed journals, books, chapters, review articles and abstracts.</p><p>Dr. Torres is board certified in Internal Medicine and Infectious Disease by the American Board of Internal Medicine. He is a member of the Infectious Disease Society of America. In 2023, he received the Excellence in Teaching Award from the Division of Infectious Disease at Montefiore Einstein. The same year, Dr. Torres received the Teaching Star-Teaching Commendation Letter for the 2022-2023 Academic Year from Montefiore Einstein.</p>

Is Open Scheduling

On

Zocdoc Link

Ivy Tam

https://assets.montefioreeinstein.org/profiles/images/physphoto/Tam_Ivy_MD_420x504.jpg

First Name

Ivy

Last Name

Tam

NPI

1427494269

Faculty ID

15947

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Pediatric Medicine

Research Focus

Dr. Tam&rsquo;s research aims to improve care and communication for patients with limited English proficiency, as well as standardizing pain practices for children.&nbsp;

Elsevier Profile

EMR ID

14829

Biography

<p>Ivy Tam, MD, FAAP, is an Attending Physician and a Non-neonatal Emergency Transport Coordinator at Children&rsquo;s Hospital at Montefiore. She is also an Assistant Professor of Pediatrics at our Albert Einstein College of Medicine. </p><p>In 2009, Dr. Tam received her Bachelor of Arts in Biological Sciences at Cornell University. She then attended SUNY Upstate Medical University, where she received her Doctor of Medicine in 2013. Dr. Tam began her postgraduate training with a residency in pediatrics at New York University School of Medicine, followed by a fellowship in pediatric hospital medicine in 2018 at the University of California San Diego. </p><p>Dr. Tam&rsquo;s research aims to improve care and communication for patients with limited English proficiency, as well as standardizing pain practices for children. She has shared her work through presentations in academic forums and scientific meetings, and is currently in the process of being submitted for publication. </p><p>2017, Dr. Tam received the CARES Award from hospital staff at Rady Children&rsquo;s Hospital for her support during the medical director&rsquo;s absence. Dr. Tam is board certified by the American Board of Pediatrics and is a member of the American Academy of Pediatrics. </p>

Is Open Scheduling

Off

Clement E. Tagoe

https://assets.montefioreeinstein.org/profiles/images/physphoto/Tagoe_Clement_MD_420x504.jpg

First Name

Clement

Last Name

Tagoe

NPI

1801985197

Faculty ID

9904

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Clement Tagoe obtained his medical degree from the University of Ghana Medical School, Ghana, and a PhD in biochemistry from the University of Leeds, UK. His basic science research interests included the study of the role of annexins in cell function and rheumatic diseases, and subsequently the mechanisms of disease in transthyretin amyloidosis using several animal models of transthyretin amyloidosis. His clinical work in the area of transthyretin amyloidosis has greatly illuminated our understanding of the form of amyloidosis associated with the Transthyretin V122I (pV142I) mutation, which is found in about 3 to 4% of African Americans. His current work focuses on the role of autoimmune diseases in fibromyalgia and chronic widespread pain, and in particular the association of these syndromes with autoimmune thyroid disease (AITD). His work also explores the other musculoskeletal and rheumatic manifestations of autoimmune thyroid disease, including the association with peripheral osteoarthritis and spinal osteoarthritis. These autoimmune syndromes can occur in the absence of thyroid dysfunction and are of particular interest to physicians and patients because AITD is by far the commonest autoimmune disease.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p class="MsoNormal"><strong>Selected Bibliography</strong></p>
<p class="MsoNormal">1. Clement E. Tagoe, Tejas Sheth, Eugeniya Golub, Karen Sorensen (2019) Rheumatic associations of autoimmune thyroid disease: a systematic review Clin Rheumatol. 2019 Jul;38(7):1801-1809., (1-9) DOI:&nbsp; 10.1007/s10067-019-04498-1</p>
<p class="MsoNormal">2. Kavisha Patel, Clement Tagoe, Phyllis Bieri, Karen Weidenheim &amp; James M. Tauras (2018): A case of transthyretin amyloidosis with myopathy, neuropathy, and cardiomyopathy resulting from an exceedingly rare mutation transthyretin Ala120Ser (c.418G &gt; T, p.Ala140Ser), Amyloid, DOI: 10.1080/13506129.2018.1491398</p>
<p class="MsoNormal">3. Daniel R. Jacobson, Alice A. Alexander, Clement Tagoe, W. Timothy Garvey, Scott M.</p>
<p class="MsoNormal">Williams, Sara Tishkoff, David Modiano, Sodiomon Bienvenu Sirima, Issa Kalidi, Toure A, &amp; Joel N. Buxbaum. The Prevalence and Distribution of the Amyloidogenic Transthyretin (TTR) V122I Allele in Africa&nbsp; Molecular Genetics &amp; Genomic Medicine Epub 14 July, 2016&nbsp; DOI: 10.1002/mgg3.231</p>
<p class="MsoNormal">4. Asha Shrestha, Hillel W. Cohen, Clement E. Tagoe. Association of Autoimmune Thyroid Disease With A Higher Frequency Of Spinal Degenerative Disc Disease Clin Exp Rheumatol. 2016 Mar-Apr;34(2):296-302. Epub 2016 Feb 9. PMID: 26885680</p>
<p class="MsoNormal">5. Tagoe CE, Zezon A, Khattri S. Rheumatic manifestations of autoimmune thyroid disease: the other autoimmune disease. J Rheumatol. 2012 Jun;39(6):1125-9. Epub 2012 Apr 15.</p>
<p>&nbsp;</p>
<p class="MsoNormal">&nbsp;</p>
<p>&nbsp;</p>

EMR ID

4680

Visit Type ID

2528

Is Open Scheduling

On

Sarah Sungurlu

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/8d27d5c0-7e34-11ec-abab-b971dcc17ab8.jpg

First Name

Sarah

Last Name

Sungurlu

NPI

1174819478

Faculty ID

17214

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

165589

Visit Type ID

2542

Is Open Scheduling

On

Kate R. Steinberg

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/05b61a40-891d-11ec-a48a-e9e0c9e20faa.jpg

First Name

Kate

Last Name

Steinberg

NPI

1528488459

Faculty ID

16973

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

141643

Visit Type ID

2542

Is Open Scheduling

On

Brian D. Spund

https://assets.montefioreeinstein.org/profiles/images/physphoto/Spund_Brian_D._MD_11121354.jpg

First Name

Brian

Last Name

Spund

NPI

1629377320

Faculty ID

15059

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

68828

Is Open Scheduling

Off

Luke R. Sponholz

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Luke

Last Name

Sponholz

NPI

1679837579

Faculty ID

18058

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

55833

Is Open Scheduling

Off

Simon D. Spivack

https://assets.montefioreeinstein.org/profiles/images/Spivack_Simon_MD_2x.jpg

First Name

Simon

Last Name

Spivack

NPI

1366438475

Faculty ID

11003

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Focusing diagnostics and therapeutics on those most likely to benefit is a key to successful intervention&nbsp;at both the public health and clinical levels. The translational goal of the Spivack laboratory is to identify individuals at particularly high risk for lung malignancy, and selected non-malignant lung diseases, upon whom to focus smoking/toxin exposure cessation (primary prevention), chemoprevention (secondary prevention), and early disease detection efforts (disease screening, tertiary prevention).</p>
<p>The laboratory is currently exploring individual Gene x Environment signatures as susceptibility markers by exploring quantitative gene (mRNA) expression phenotypes, and the DNA sequence, methylation, microRNA, and other epigenetic features potentially underlying these expression phenotypes, <em>in vitro</em> and in human populations. This is performed in the setting of defined tobacco, diet, and other exposures. There are both mechanistic and translational components to the studies.&nbsp;</p>
<p><br /><strong>Mechanistically</strong>, the role of epigenetic variation in promoter regions in the 5' and 3' regulatory regions of carcinogenesis and oxidant pathway genes is being explored <em>in vitro</em>, using human genomic DNA reporter constructs, and native gene regulation models. High resolution technologies include the realtime quantitation of native mRNA and microRNA by the laboratory's RNA-specific strategy (<em>patented</em>); the&nbsp;tagged-bisulfite genomic sequencing strategy to determine single base resolution CpG methylation status (tBGS, <em>patented</em>);&nbsp;&nbsp;an experimental strategy for assaying microRNA binding to mRNA, for determining the role of miRNA in candidate gene regulation&nbsp;(<em>patented</em>); and evaluation of functional consequences of DNA&nbsp;methylation detail, using a novel patch reporter construct (<em>patented</em>).&nbsp; A new method to engineer methyl-cytosines into the epigenome has recently been developed.</p>
<p>Whole (epi)genome approaches to identify molecular events unique to lung cancer&nbsp;are being completed, which will represent one of the initial cross-platform 'omics level discovery examinations of&nbsp;lung&nbsp;tissues.&nbsp; The execution of each individual discovery platform involves&nbsp;expert local collaborators and cores&nbsp;in (epi)genetics and genomics, and the "integromics" is critically reliant on Einstein strengths in informatics and biostatistical analyses.</p>
<p>&nbsp;</p>
<p><strong>Translationally</strong>, human lung carcinogenesis biomarkers are being established by pairing laser capture microdissected lung with several unique, non-invasively collected surrogate specimens developed in the laboratory. These include mRNA expression signatures from brush-exfoliated buccal mucosa cells, microRNAs detected in exhaled breath condensate representing first reports for a new exhaled airway biomarker class, and exhaled metabolomic signatures. These airway-derived specimens continue to accrue from a sampling (currently n&gt;1000) of a population assembled in a lung cancer case-control context.&nbsp; The specimens are being studied with a view toward developing non-invasive assays in populations.</p>
<p>&nbsp;</p>
<p>The overall aim is to develop informative non-invasive risk profiling, preventive, and early disease detection strategies for the lung in human populations.</p>
<p>&nbsp;</p>
<p>&nbsp;<em>Work is funded by ongoing NIH,</em><em> DoD,&nbsp;and&nbsp;Foundation support.</em></p>
<p>&nbsp;</p>
<p><strong>Clinical Specialties</strong></p>
<ul style="font-size: 1em; color: #333333; padding: 0px; margin: 20px 0px 25px 38px;">
<li style="padding: 0px; margin: 12px 0px 5px 0px;">lung nodule evaluation</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">lung cancer diagnostics and screening</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">interstitial lung disease</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">environmental lung disease</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">refractory asthma</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">general pulmonary medicine</li>
</ul>

Research Areas

Expert Tags

Areas of Expertise

Expert Summary

<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt;">A researcher and clinician, Dr. Spivack is developing tests for detecting lung cancer at the earliest possible stage&mdash;before it becomes fatal by spreading to other parts of the body. In one of several NIH-funded studies, his laboratory is working on a noninvasive, early-diagnosis test for lung cancer that detects particular genetic elements and chemicals in exhaled breath.</span></p>
<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt;">In addition to general pulmonary medicine, Dr. Spivack&rsquo;s clinical practice focuses on lung nodule and lung cancer diagnosis, diffuse interstitial lung diseases, and environmental lung diseases.</span></p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Spivack specializes in consultative pulmonary medicine, with an emphasis on the evaluation of lung nodules, lung cancer screening, asthma, and environmental and interstitial lung disease.<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;"><strong></strong></span>

Research Focus

Dr. Spivack&rsquo;s research focuses on the development of non-invasive early detection airway biomarkers of lung cancer risk, as well as epigenetics, gene regulation, gene-environment interaction and non-invasive measurement of deep lung phenomena in humans.

Elsevier Profile

Selected Publications

<ol>
<li>Zhenqiu Huang, Alex Maslov, Xiao Dong, Shixiang Sun, Moonsook Lee, Chirag Shah, Ali Sadoughi, Aditi Desai, Dhruv Patel, Taha Siddiqui, Jaiminkumar Patel, Miao Shi, Spencer Waldman, Ava Marsh, Yakov Peter, <strong>*Simon D Spivack,</strong> *Jan Vijg. Somatic Mutations At Single Base Resolution in Single Bronchial Progenitor Cells Collected From Human Lung. <em>(Nature Genetics, April 2022, </em><a href="https://www.nature.com/articles/s41588-022-01035-w&quot; target="_blank">https://www.nature.com/articles/s41588-022-01035-w</a&gt;). (*co-senior authors).</li>
<li>Shi M, Han W, Loudig O, Shah CD, Dobkin JB, Keller S, Sadoughi A, Zhu C, Siegel RE, Fernandez MK, DeLaRosa L, Patel D, Desai A, Siddiqui T, Gombar S, Suh Y, Wang T, Hosgood HD, Pradhan K, Ye K, <strong>Spivack SD.</strong> Initial development and testing of an exhaled microRNA detection strategy for lung cancer case-control discrimination. Sci Rep. 2023 Apr 24;13(1):6620. doi: 10.1038/s41598-023-33698-8. PMID: 37095155; PMCID: PMC10126132.</li>
<li>Yoo EJ, Kim JS, Stransky S, <strong>Spivack S,</strong> Sidoli S. Advances in proteomics methods for the analysis of exhaled breath condensate. Mass Spectrom Rev. 2024 Jul-Aug;43(4):713-722. doi: 10.1002/mas.21871. Epub 2023 Dec 27. PMID: 38149478.</li>
<li>Zefi O, Waldman S, Marsh A, Shi MK, Sonbolian Y, Khulan B, Siddiqui T, Desai A, Patel D, Okorozo A, Khader S, Dobkin J, Sadoughi A, Shah C, <strong>*Spivack S,</strong> *Peter Y. Distinctive field effects of smoking and lung cancer case-control status on bronchial basal cell growth and signaling. Respir Res. 2024 Aug 19;25(1):317. doi: 10.1186/s12931-024-02924-w. PMID: 39160511; PMCID: PMC11334309. *(co-senior authors)</li>
<li>Mitchell MI, Ben-Dov IZ, Ye K, Liu C, Shi M, Sadoughi A, Shah C, Siddiqui T, Okorozo A, Gutierrez M, Unawane R, Biamonte L, Parikh K, <strong>Spivack S,</strong> Loudig O. Exhaled breath condensate contains extracellular vesicles (EVs) that carry miRNA cargos of lung tissue origin that can be selectively purified and analyzed. J Extracell Vesicles. 2024 Apr;13(4):e12440. doi: 10.1002/jev2.12440. Erratum in: J Extracell Vesicles. 2024 May;13(5):e12453. doi: 10.1002/jev2.12453. PMID: 38659349; PMCID: PMC11043690.</li>
<li>Khulan B, Ye K, Shi MK, Waldman S, Marsh A, Siddiqui T, Okorozo A, Desai A, Patel D, Dobkin J, Sadoughi A, Shah C, Gera S, Peter Y, Liao W, *Vijg J, *<strong>Spivack SD</strong>. Normal bronchial field basal cells show persistent methylome-wide impact of tobacco smoking, including in known cancer genes. Epigenetics. 2025 Dec;20(1):2466382. doi: 10.1080/15592294.2025.2466382. Epub 2025 Feb 20. PMID: 39980243; PMCID: PMC11849931. *(co-senior authors)</li>
</ol>

EMR ID

4969

Biography

<p>Simon D. Spivack, MD, MPH, is Professor, Medicine, Epidemiology and Genetics at Montefiore Einstein. He is also former Emeritus Chief, Pulmonary Medicine. Clinically, Dr. Spivack specializes in consultative pulmonary medicine, with an emphasis on the evaluation of lung nodules, lung cancer screening, asthma, and environmental and interstitial lung disease. </p><p>After obtaining his Bachelor of Science in Psychobiology from McGill University in Montreal, Canada in 1980, Dr. Spivack earned his Doctor of Medicine from the State University of New York Upstate Medical University in 1985. He then completed an internship and residency in internal medicine at the University of Massachusetts Medical Center in 1988. Dr. Spivack then earned his Master of Public Health at Harvard University, School of Public Health in 1989. He completed a clinical pulmonary and critical care medicine and lung research fellowship at the University of Vermont in 1992. </p><p>Dr. Spivack&rsquo;s research focuses on the development of non-invasive early detection airway biomarkers of lung cancer risk, as well as epigenetics, gene regulation, gene-environment interaction and non-invasive measurement of deep lung phenomena in humans. His work has been published in numerous peer-reviewed journals, articles, chapters and books, and he has given many national/international presentations, organized symposia and visiting professorships. Dr. Spivack is on the Editorial Board for Scientific Reports and is a reviewer for journals such as <em>PLoS Genetics</em>, <em>Genetics in Medicine</em>, <em>Nature Protocols</em>, <em>American Journal of Respiratory &amp; Critical Care Medicine</em>, <em>Carcinogenesis</em>, <em>Cancer Research</em> and others. He holds multiple United States patents. He has been continually funded by the National Institutes of Health (NIH) for research for over 25 years.
</p><p>Dr. Spivack is board certified in internal medicine, pulmonary medicine and critical care medicine. He is a member of the American Thoracic Society (ATS), the American Association for Cancer Research (AACR) and the American Lung Association (ALA). He is a frequent peer-reviewer on various NIH study sections. In the past, Dr. Spivack won the Excellence in Research Award from ALA and the NIH/National Institute of Environmental Health Sciences (NIEHS) Clinical Scientist Development Award.

</p>

Visit Type ID

2542

Is Open Scheduling

On

Zocdoc Link

Olena Slinchenkova

https://assets.montefioreeinstein.org/profiles/images/physphoto/Slinchenkova_Olena_MD_420x504.jpg

First Name

Olena

Last Name

Slinchenkova

NPI

1013205632

Faculty ID

14967

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

55793

Is Open Scheduling

Off

Sumeet Singh-Tan

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/d41fe610-497e-11ec-8149-d1681d4b2362.jpg

First Name

Sumeet

Last Name

Singh-Tan

NPI

1215318001

Faculty ID

16569

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

14316

Is Open Scheduling

Off